In January Prana was most likely working with the main...

In January Prana was most likely working with the main shareholders to get the Sinclair deal accepted in the shareholder meeting within 90 days, latest in the end of March. After the Bohlmann paper IMO they need to get back to these shareholders and tell that now they want that they will reject this Sinclair proposal to get a better deal including PBT2 antibacterial effect. 
Then Prana needs to work to get a new patent for PBT2 and negotiate how the Bohlmann group will be rewarded in this new patent.
After this Prana needs to find a new deal with Sinclair or find new partners. Now it has more to negotiate of, PBT2 to the market !

This is a lot of work for a small company. May be this is the reason we have not got any info from them.